To include your compound in the COVID-19 Resource Center, submit it here.

The'FIDO' Strategy Behind Onyx Deal

By BC Staff | May 9, 1994 | 7:00 AM GMT
The 'FIDO' strategy behind Onyx deal

Onyx Pharmaceuticals' five-year R&D agreement with Miles Inc. illustrates the value research boutiques can garner from their skills, according to Hollings Renton, president and CEO.

The deal, worth up to $75 million,

Read the full 389 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE